Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with histor

worldpharmanewsAugust 25, 2017

Tag: AstraZeneca , Brilinta

PharmaSources Customer Service